Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Co-targeting c-Met and COX-2 leads to enhanced inhibition of lung tumorigenesis in a murine model with heightened airway HGF.

Stabile LP, Rothstein ME, Gubish CT, Cunningham DE, Lee N, Siegfried JM.

J Thorac Oncol. 2014 Sep;9(9):1285-93. doi: 10.1097/JTO.0000000000000245.

2.

c-Src activation mediates erlotinib resistance in head and neck cancer by stimulating c-Met.

Stabile LP, He G, Lui VW, Thomas S, Henry C, Gubish CT, Joyce S, Quesnelle KM, Siegfried JM, Grandis JR.

Clin Cancer Res. 2013 Jan 15;19(2):380-92. doi: 10.1158/1078-0432.CCR-12-1555. Epub 2012 Dec 4. Erratum in: Clin Cancer Res. 2013 Jul 1;19(13):3715. Thomas, Sufi [added].

3.

Combining the multitargeted tyrosine kinase inhibitor vandetanib with the antiestrogen fulvestrant enhances its antitumor effect in non-small cell lung cancer.

Siegfried JM, Gubish CT, Rothstein ME, Henry C, Stabile LP.

J Thorac Oncol. 2012 Mar;7(3):485-95. doi: 10.1097/JTO.0b013e31824177ea.

4.

Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells.

Xu H, Stabile LP, Gubish CT, Gooding WE, Grandis JR, Siegfried JM.

Clin Cancer Res. 2011 Jul 1;17(13):4425-38. doi: 10.1158/1078-0432.CCR-10-3339. Epub 2011 May 27.

5.

HGF-independent potentiation of EGFR action by c-Met.

Dulak AM, Gubish CT, Stabile LP, Henry C, Siegfried JM.

Oncogene. 2011 Aug 18;30(33):3625-35. doi: 10.1038/onc.2011.84. Epub 2011 Mar 21.

6.

HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer.

Knowles LM, Stabile LP, Egloff AM, Rothstein ME, Thomas SM, Gubish CT, Lerner EC, Seethala RR, Suzuki S, Quesnelle KM, Morgan S, Ferris RL, Grandis JR, Siegfried JM.

Clin Cancer Res. 2009 Jun 1;15(11):3740-50. doi: 10.1158/1078-0432.CCR-08-3252. Epub 2009 May 26.

7.

Estrogen receptor beta (ERbeta) subtype-specific ligands increase transcription, p44/p42 mitogen activated protein kinase (MAPK) activation and growth in human non-small cell lung cancer cells.

Hershberger PA, Stabile LP, Kanterewicz B, Rothstein ME, Gubish CT, Land S, Shuai Y, Siegfried JM, Nichols M.

J Steroid Biochem Mol Biol. 2009 Aug;116(1-2):102-9. doi: 10.1016/j.jsbmb.2009.05.004. Epub 2009 May 19.

8.

Signaling pathways involved in cyclooxygenase-2 induction by hepatocyte growth factor in non small-cell lung cancer.

Siegfried JM, Gubish CT, Rothstein ME, Queiroz de Oliveira PE, Stabile LP.

Mol Pharmacol. 2007 Sep;72(3):769-79. Epub 2007 Jun 5.

PMID:
17550984
9.

Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer.

Zhang Q, Bhola NE, Lui VW, Siwak DR, Thomas SM, Gubish CT, Siegfried JM, Mills GB, Shin D, Grandis JR.

Mol Cancer Ther. 2007 Apr;6(4):1414-24.

10.
11.

Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen.

Stabile LP, Davis AL, Gubish CT, Hopkins TM, Luketich JD, Christie N, Finkelstein S, Siegfried JM.

Cancer Res. 2002 Apr 1;62(7):2141-50.

12.

Sex-specific expression of gastrin-releasing peptide receptor: relationship to smoking history and risk of lung cancer.

Shriver SP, Bourdeau HA, Gubish CT, Tirpak DL, Davis AL, Luketich JD, Siegfried JM.

J Natl Cancer Inst. 2000 Jan 5;92(1):24-33.

PMID:
10620630
13.

The clinical significance of hepatocyte growth factor for non-small cell lung cancer.

Siegfried JM, Weissfeld LA, Luketich JD, Weyant RJ, Gubish CT, Landreneau RJ.

Ann Thorac Surg. 1998 Dec;66(6):1915-8.

PMID:
9930468
14.

Activity of anti-erbB-2 recombinant toxin OLX-209 on lung cancer cell lines in the absence of erbB-2 gene amplification.

Kasprzyk PG, Sullivan TL, Hunt JD, Gubish CT, Scoppa CA, Oelkuct M, Bird R, Fischer PH, Siegfried JM, King CR.

Clin Cancer Res. 1996 Jan;2(1):75-80.

15.

Zinc nutritional status modulates the response of 1,25-dihydroxycholecalciferol to calcium depletion in rats.

Kimmel PL, Gubish CT, Watkins DW, Langman CB.

J Nutr. 1992 Jul;122(7):1576-81.

PMID:
1619482
16.

Zinc nutritional status modulates the 1,25-(OH)2D. Response in uremic rats.

Kimmel PL, Watkins DW, Gubish CT, Slatopolsky E, Langman CB.

Miner Electrolyte Metab. 1991;17(5):307-14.

PMID:
1819762

Supplemental Content

Loading ...
Support Center